Endometrial Cancer

Obstetrics and Gynecology Clinics of North America

Volumn 39, Issue 2, 2012, Pages 255-268

  Leslie, Kimberly K ^a   Thiel, Kristina W ^a   Goodheart, Michael J ^a   De Geest, Koen ^a   Jia, Yichen ^a   Yang, Shujie ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Chemotherapy; Diagnosis; Ensdometrial cancer; Estrogen; Progesterone; Risk factors; Treatment

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; AROMATASE INHIBITOR; BEVACIZUMAB; CISPLATIN; DNA METHYLTRANSFERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; FULVESTRANT; GEMCITABINE; GESTAGEN; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; LEUPRORELIN; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; TAMOXIFEN; TEMSIROLIMUS;

BRACHYTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; ENDOMETRIUM CANCER; EXTERNAL BEAM RADIOTHERAPY; GYNECOLOGIC SURGERY; HIGH RISK PATIENT; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; UNSPECIFIED SIDE EFFECT;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; HYSTERECTOMY; LYMPH NODE EXCISION; MIDDLE AGED; MOLECULAR TARGETED THERAPY; OBESITY; POSTMENOPAUSE; PROGNOSIS; RISK FACTORS; UNITED STATES; UTERINE HEMORRHAGE;

EID: 84861515979     PISSN: 08898545     EISSN: 15580474     Source Type: Journal    
DOI: 10.1016/j.ogc.2012.04.001     Document Type: Review

References (79)

1. Cancer Facts and Figures 2011 American Cancer Society, Accessed November 21, 2011. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-029771.pdf.
2. Schmandt R.E., Iglesias D.A., Co N.N., et al. Understanding obesity and endometrial cancer risk: opportunities for prevention. Am J Obstet Gynecol 2011, 205(6):518-525.
3. Kurman R.J., Kaminski P.F., Norris H.J. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985, 56(2):403-412.
4. Trimble C.L., Kauderer J., Zaino R., et al. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006, 106(4):812-819.
5. Shutter J., Wright T.C. Prevalence of underlying adenocarcinoma in women with atypical endometrial hyperplasia. Int J Gynecol Pathol 2005, 24(4):313-318.
6. Hahn H.S., Chun Y.K., Kwon Y.I., et al. Concurrent endometrial carcinoma following hysterectomy for atypical endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol 2010, 150(1):80-83.
7. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009, 105(2):103-104.
8. Mutch D.G. The New FIGO staging system for cancers of the vulva, cervix, endometrium, and sarcomas. Gynecol Oncol 2009, 115:325-328.
9. Creasman W.T., Odicino F., Maisonneuve P., et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006, 95(Suppl 1):S105-S143.
10. Gultekin M., Yildiz F., Ozyigit G., et al. Comparison of FIGO 1988 and 2009 staging systems for endometrial carcinoma. Med Oncol 2012, [Epub ahead of print].
11. Page B.R., Pappas L., Cooke E.W., et al. Does the FIGO 2009 endometrial cancer staging system more accurately correlate with clinical outcome in different histologies?: revised staging, endometrial cancer, histology. Int J Gynecol Cancer 2012, [Epub ahead of print].
12. Milam M.R., Java J., Walker J.L., et al. Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol 2012, 119(2 Pt 1):286-292.
13. Creasman W.T., Morrow C.P., Bundy B.N., et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987, 60(8 Suppl):2035-2041.
14. Morrow C.P., Bundy B.N., Kurman R.J., et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991, 40(1):55-65.
15. Lurain J.R., Rice B.L., Rademaker A.W., et al. Prognostic factors associated with recurrence in clinical stage I adenocarcinoma of the endometrium. Obstet Gynecol 1991, 78(1):63-69.
16. Kitchener H., Swart A.M., Qian Q., et al. Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet 2009, 373(9658):125-136.
17. Benedetti Panici P., Basile S., Maneschi F., et al. Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst 2008, 100(23):1707-1716.
18. Orr J.W., Holloway R.W., Orr P.F., et al. Surgical staging of uterine cancer: an analysis of perioperative morbidity. Gynecol Oncol 1991, 42(3):209-216.
19. Walker J.L., Piedmonte M.R., Spirtos N.M., et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. J Clin Oncol 2009, 27(32):5331-5336.
20. Mariani A., Dowdy S.C., Cliby W.A., et al. Prospective assessment of lymphatic dissemination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 2008, 109(1):11-18.
21. Brown A.J., Westin S.N., Broaddus R.R., et al. Progestin intrauterine device in an adolescent with grade 2 endometrial cancer. Obstet Gynecol 2012, 119(2 Pt 2):423-426.
22. Leslie K.K., Thiel K.W., Yang S. Endometrial cancer: potential treatment and prevention with progestin-containing intrauterine devices. Obstet Gynecol 2012, 119(2 Pt 2):419-420.
23. Keys H.M., Roberts J.A., Brunetto V.L., et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004, 92(3):744-751.
24. Creutzberg C.L., van Putten W., Koper P.C., et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000, 355(9213):1404-1411.
25. Nout R.A., Smit V.T., Putter H., et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010, 375(9717):816-823.
26. Nout R.A., van de Poll-Franse L.V., Lybeert M.L., et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol 2011, 29(13):1692-1700.
27. Nout R.A., Putter H., Jurgenliemk-Schulz I.M., et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data. Eur J Cancer 2011, [Epub ahead of print].
28. Delahanty R.J., Beeghly-Fadiel A., Xiang Y.B., et al. Association of obesity-related genetic variants with endometrial cancer risk: a report from the Shanghai Endometrial Cancer Genetics Study. Am J Epidemiol 2011, 174(10):1115-1126.
29. Chen X., Xiang Y.B., Long J.R., et al. Genetic polymorphisms in obesity-related genes and endometrial cancer risk. Cancer 2011, [Epub ahead of print].
30. Fleming G.F., Brunetto V.L., Cella D., et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004, 22(11):2159-2166.
31. Hoskins P.J., Swenerton K.D., Pike J.A., et al. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 2001, 19(20):4048-4053.
32. Sorbe B., Andersson H., Boman K., et al. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int J Gynecol Cancer 2008, 18(4):803-808.
33. Sovak M.A., Dupont J., Hensley M.L., et al. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int J Gynecol Cancer 2007, 17(1):197-203.
34. Itamochi H. Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. World J Biol Chem 2010, 1(7):209-220.
35. Temkin S.M., Fleming G. Current treatment of metastatic endometrial cancer. Cancer Control 2009, 16(1):38-45.
36. Leslie K.K., Laidler L.L., Albitar L., et al. Tyrosine kinase inhibitors in endometrial cancer. Int J Gynecol Cancer 2005, 15:409-411.
37. Zagouri F., Bozas G., Kafantari E., et al. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?. Obstet Gynecol Int 2010, 2010:749579.
38. Sherman M.E., Sturgeon S., Brinton L., et al. Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis. J Cell Biochem Suppl 1995, 23:160-164.
39. Enomoto T., Inoue M., Perantoni A.O., et al. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 1991, 51(19):5308-5314.
40. Risinger J.I., Hayes A.K., Berchuck A., et al. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997, 57(21):4736-4738.
41. Mutter G.L., Lin M.C., Fitzgerald J.T., et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers [see comments]. J Natl Cancer Inst 2000, 92(11):924-930.
42. Ryan A.J., Susil B., Jobling T.W., et al. Endometrial cancer. Cell Tissue Res 2005, 322(1):53-61.
43. Okuda T., Sekizawa A., Purwosunu Y., et al. Genetics of endometrial cancers. Obstet Gynecol Int 2010, 2010:984013.
44. Moll U.M., Chalas E., Auguste M., et al. Uterine papillary serous carcinoma evolves via a p53-driven pathway. Hum Pathol 1996, 27(12):1295-1300.
45. Zheng W., Cao P., Zheng M., et al. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 1996, 61(2):167-174.
46. Kounelis S., Kapranos N., Kouri E., et al. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 2000, 13(4):379-388.
47. Singh M., Darcy K.M., Brady W.E., et al. Cadherins, catenins and cell cycle regulators: impact on survival in a Gynecologic Oncology Group phase II endometrial cancer trial. Gynecol Oncol 2011, 123(2):320-328.
48. Leslie K.K., Stein M.P., Kumar N.S., et al. Progesterone receptor isoform identification and subcellular localization in endometrial cancer. Gynecol Oncol 2005, 96(1):32-41.
49. Ali I.U. Gatekeeper for endometrium: the PTEN tumor suppressor gene. J Natl Cancer Inst 2000, 92(11):861-863.
50. Tashiro H., Blazes M.S., Wu R., et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997, 57(18):3935-3940.
51. Rosenwald I.B., Rhoads D.B., Callanan L.D., et al. Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc. Proc Natl Acad Sci U S A 1993, 90(13):6175-6178.
52. Byron S.A., Gartside M., Powell M.A., et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One 2012, 7(2):e30801.
53. Horst D., Chen J., Morikawa T., et al. Differential WNT activity in colorectal cancer confers limited tumorigenic potential and is regulated by MAPK signaling. Cancer Res 2012, 72(6):1547-1556.
54. Furness S., Roberts H., Marjoribanks J., et al. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2009, 2. CD000402.
55. Yang S., Thiel K.W., De Geest K., et al. Endometrial cancer: reviving progesterone therapy in the molecular age. Discov Med 2011, 12(64):205-212.
56. Yang S., Thiel K.W., Leslie K.K. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab 2011, 22(4):145-152.
57. Kim J.J., Chapman-Davis E. Role of progesterone in endometrial cancer. Semin Reprod Med 2010, 28(1):81-90.
58. Ehrlich C.E., Young P.C., Stehman F.B., et al. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 1988, 158(4):796-807.
59. Satyaswaroop P.G., Clarke C.L., Zaino R.J., et al. Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor. Cancer Lett 1992, 62(2):107-114.
60. Mortel R., Zaino R.J., Satyaswaroop P.G. Designing a schedule of progestin administration in the control of endometrial carcinoma growth in the nude mouse model. Am J Obstet Gynecol 1990, 162(4):928-934. [discussion: 934-6].
61. Dai D., Kumar N.S., Wolf D.M., et al. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation. Am J Obstet Gynecol 2001, 184(5):790-797.
62. Whitney C.W., Brunetto V.L., Zaino R.J., et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004, 92(1):4-9.
63. Singh M., Zaino R.J., Filiaci V.J., et al. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2007, 106(2):325-333.
64. Sasaki M., Dharia A., Oh B.R., et al. Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Res 2001, 61(1):97-102.
65. Ren Y., Liu X., Ma D., et al. Down-regulation of the progesterone receptor by the methylation of progesterone receptor gene in endometrial cancer cells. Cancer Genet Cytogenet 2007, 175(2):107-116.
66. Xiong Y., Dowdy S.C., Gonzalez Bosquet J., et al. Epigenetic-mediated upregulation of progesterone receptor B gene in endometrial cancer cell lines. Gynecol Oncol 2005, 99(1):135-141.
67. Thigpen T., Brady M.F., Homesley H.D., et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2001, 19(2):364-367.
68. Covens A., Thomas G., Shaw P., et al. A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol 1997, 64(1):126-129.
69. Covens A.L., Filiaci V., Gersell D., et al. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2011, 120(2):185-188.
70. Rose P.G., Brunetto V.L., VanLe L., et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2000, 78(2):212-216.
71. Ma B.B., Oza A., Eisenhauer E., et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers-a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 2004, 14(4):650-658.
72. Aghajanian C., Sill M.W., Darcy K.M., et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011, 29(16):2259-2265.
73. Oza A.M., Elit L., Tsao M.S., et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011, 29(24):3278-3285.
74. Oza A.M., Elit L., Biagi J., et al. Molecular correlates associated with a phase II study of temsirolimus (Temsirolimus) in patients with metastatic or recurrent endometrial cancer-NCIC IND 160. Proc Am Soc Clin Oncol 2006, 24(18s):121s. [abstr: 3003].
75. Oza A.M., Eisenhauer E.A., Elit L., et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008, 26(26):4319-4325.
76. Jubb A.M., Hurwitz H.I., Bai W., et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006, 24(2):217-227.
77. Yang S., Xiao X., Meng X., et al. A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One 2011, 6(10):e26343.
78. Hay T., Matthews J.R., Pietzka L., et al. Poly(ADP-ribose) polymerase-1 inhibitor treatment regresses autochthonous Brca2/p53-mutant mammary tumors in vivo and delays tumor relapse in combination with carboplatin. Cancer Res 2009, 69(9):3850-3855.
79. Miller DS. Randomized Phase III Noninferiority Trial of First Line Chemotherapy for Metastatic or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study, in Society of Gynecologic Oncology Meeting. Austin, TX; 2012.